Symbols / MIRM Stock $106.88 +0.67% Mirum Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NGM
MIRM (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Christopher Peetz
Exch · Country NGM · United States
Market Cap 6.52B
Enterprise Value 6.46B
Income -798.84M
Sales 569.61M
FCF (ttm) 166.90M
Book/sh 3.98
Cash/sh 6.33
Employees 418
Insider 10d —
IPO Jul 18, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -191.54
PEG —
P/S 11.44
P/B 26.85
P/C —
EV/EBITDA -128.97
EV/Sales 11.33
Quick Ratio 1.90
Current Ratio 2.09
Debt/Eq 133.52
LT Debt/Eq —
EPS (ttm) -13.60
EPS next Y -0.56
EPS Growth —
Revenue Growth 43.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-06
ROA -5.94%
ROE -3.36%
ROIC —
Gross Margin 81.39%
Oper. Margin -39.51%
Profit Margin -140.24%
Shs Outstand 60.98M
Shs Float 53.07M
Insider Own 1.36%
Instit Own 106.81%
Short Float 18.10%
Short Ratio 11.48
Short Interest 8.41M
52W High 112.00
vs 52W High -4.57%
52W Low 42.89
vs 52W Low 149.20%
Beta 0.52
Impl. Vol. 74.95%
Rel Volume 0.75
Avg Volume 882.87K
Volume 660.24K
Target (mean) $146.36
Tgt Median $140.00
Tgt Low $129.00
Tgt High $185.00
# Analysts 11
Recom Strong_buy
Prev Close $106.17
Price $106.88
Change 0.67%
About

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$146.36
Mean price target
2. Current target
$106.88
Latest analyst target
3. DCF / Fair value
$49.26
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$106.88
Low
$129.00
High
$185.00
Mean
$146.36

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-07 main TD Cowen Buy → Buy $145
2026-05-07 main RBC Capital Outperform → Outperform $142
2026-05-07 main Evercore ISI Group Outperform → Outperform $138
2026-05-07 main Baird Outperform → Outperform $129
2026-05-05 main Morgan Stanley Overweight → Overweight $140
2026-05-04 main HC Wainwright & Co. Buy → Buy $175
2026-04-29 main Stifel Buy → Buy $130
2026-04-28 main Baird Outperform → Outperform $112
2026-04-27 main HC Wainwright & Co. Buy → Buy $150
2026-04-21 reit Citizens Market Outperform → Market Outperform $132
2026-03-27 main TD Cowen Buy → Buy $125
2026-03-23 reit HC Wainwright & Co. Buy → Buy $130
2026-03-04 main Evercore ISI Group Outperform → Outperform $126
2026-02-26 main Leerink Partners Outperform → Outperform $118
2026-02-26 main TD Cowen Buy → Buy $117
2026-02-26 main RBC Capital Outperform → Outperform $128
2026-02-26 main Citizens Market Outperform → Market Outperform $132
2026-02-26 main Stifel Buy → Buy $125
2026-02-18 init RBC Capital — → Outperform $130
2026-01-30 main Morgan Stanley Overweight → Overweight $123
News
RSS: Latest MIRM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-15 RAMASASTRY SAIRA Director — 2,000 $96.90 $193,800
2026-04-15 RAMASASTRY SAIRA Director — 2,000 $23.51 $47,020
2026-03-16 RAMASASTRY SAIRA Director — 2,000 $90.76 $181,520
2026-03-16 BJERKHOLT ERIC H Chief Financial Officer — 7,287 $91.98 $670,243
2026-03-16 PEETZ CHRISTOPHER Chief Executive Officer — 40,985 $91.98 $3,769,714
2026-03-16 RADOVICH PETER President — 16,515 $91.98 $1,519,015
2026-03-16 QUAN JOANNE Officer — 7,287 $91.98 $670,243
2026-03-16 HOWE JOLANDA MARIE Officer — 4,732 $91.98 $435,239
2026-03-16 RAMASASTRY SAIRA Director — 2,000 $23.51 $47,020
2026-03-13 BJERKHOLT ERIC H Chief Financial Officer — 13,334 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
521.31
+54.74%
336.89
+80.76%
186.37
+141.85%
77.06
Operating Revenue
521.31
+54.74%
336.89
+80.76%
186.37
+141.85%
77.06
Cost Of Revenue
100.24
+22.78%
81.64
+73.56%
47.04
+280.14%
12.37
Reconciled Cost Of Revenue
100.24
+22.78%
81.64
+73.56%
47.04
+280.14%
12.37
Gross Profit
421.07
+64.97%
255.25
+83.19%
139.34
+115.40%
64.69
Operating Expense
443.21
+29.27%
342.85
+37.97%
248.49
+26.84%
195.91
Research And Development
186.18
+32.39%
140.63
+37.05%
102.61
-3.96%
106.84
Selling General And Administration
257.03
+27.10%
202.22
+38.62%
145.88
+63.79%
89.07
Total Expenses
543.45
+28.02%
424.49
+43.64%
295.53
+41.89%
208.28
Operating Income
-22.14
+74.73%
-87.61
+19.74%
-109.15
+16.82%
-131.22
Total Operating Income As Reported
-22.14
+74.73%
-87.61
+19.74%
-109.15
+16.82%
-131.22
EBITDA
17.21
+135.13%
-48.97
+64.12%
-136.49
-11.10%
-122.85
Normalized EBITDA
17.21
+135.13%
-48.97
+43.98%
-87.41
+29.37%
-123.76
Reconciled Depreciation
24.24
+2.60%
23.63
+118.20%
10.83
+234.43%
3.24
EBIT
-7.04
+90.31%
-72.60
+50.72%
-147.32
-16.83%
-126.09
Total Unusual Items
0.00
0.00
+100.00%
-49.08
-5516.78%
0.91
Total Unusual Items Excluding Goodwill
0.00
0.00
+100.00%
-49.08
-5516.78%
0.91
Special Income Charges
0.00
0.00
+100.00%
-49.08
0.00
Other Special Charges
—
—
49.08
—
Net Income
-23.36
+73.43%
-87.94
+46.18%
-163.41
-20.45%
-135.66
Pretax Income
-21.43
+75.35%
-86.91
+46.49%
-162.42
-14.33%
-142.07
Net Non Operating Interest Income Expense
-1.66
-220.23%
-0.52
+62.12%
-1.37
+88.70%
-12.12
Interest Expense Non Operating
14.39
+0.55%
14.31
-5.26%
15.11
-5.47%
15.98
Net Interest Income
-1.66
-220.23%
-0.52
+62.12%
-1.37
+88.70%
-12.12
Interest Expense
14.39
+0.55%
14.31
-5.26%
15.11
-5.47%
15.98
Interest Income Non Operating
12.73
-7.72%
13.79
+0.41%
13.73
+256.11%
3.86
Interest Income
12.73
-7.72%
13.79
+0.41%
13.73
+256.11%
3.86
Other Income Expense
2.37
+95.47%
1.21
+102.34%
-51.90
-4183.40%
1.27
Other Non Operating Income Expenses
2.37
+95.47%
1.21
+142.95%
-2.82
-873.70%
0.36
Gain On Sale Of Security
—
—
—
0.91
Tax Provision
1.94
+87.96%
1.03
+3.94%
0.99
+115.47%
-6.41
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+365.63%
0.00
Tax Effect Of Unusual Items
0.00
0.00
+100.00%
-10.31
-25322.24%
0.04
Net Income Including Noncontrolling Interests
-23.36
+73.43%
-87.94
+46.18%
-163.41
-20.45%
-135.66
Net Income From Continuing Operation Net Minority Interest
-23.36
+73.43%
-87.94
+46.18%
-163.41
-20.45%
-135.66
Net Income From Continuing And Discontinued Operation
-23.36
+73.43%
-87.94
+46.18%
-163.41
-20.45%
-135.66
Net Income Continuous Operations
-23.36
+73.43%
-87.94
+46.18%
-163.41
-20.45%
-135.66
Normalized Income
-23.36
+73.43%
-87.94
+29.45%
-124.64
+8.71%
-136.53
Net Income Common Stockholders
-23.36
+73.43%
-87.94
+46.18%
-163.41
-20.45%
-135.66
Diluted EPS
-0.47
+74.59%
-1.85
+53.05%
-3.94
+1.99%
-4.02
Basic EPS
-0.47
+74.59%
-1.85
+53.05%
-3.94
+1.75%
-4.01
Basic Average Shares
50.20
+5.63%
47.52
+16.23%
40.89
+20.82%
33.84
Diluted Average Shares
50.20
+5.63%
47.52
+16.23%
40.89
+20.31%
33.98
Diluted NI Availto Com Stockholders
-23.36
+73.43%
-87.94
+46.18%
-163.41
-19.65%
-136.58
Average Dilution Earnings
—
0.00
0.00
+100.00%
-0.91
Line Item Trend 2021-12-31
Total Assets
—
Current Assets
—
Cash Cash Equivalents And Short Term Investments
—
Cash And Cash Equivalents
—
Other Short Term Investments
—
Receivables
—
Accounts Receivable
—
Inventory
—
Raw Materials
—
Work In Process
—
Finished Goods
—
Prepaid Assets
5.27
Other Current Assets
—
Total Non Current Assets
—
Net PPE
—
Gross PPE
—
Properties
0.00
Buildings And Improvements
1.57
Other Properties
—
Goodwill And Other Intangible Assets
—
Other Intangible Assets
—
Investments And Advances
—
Other Non Current Assets
—
Total Liabilities Net Minority Interest
—
Current Liabilities
—
Payables And Accrued Expenses
—
Payables
—
Accounts Payable
—
Other Payable
—
Current Accrued Expenses
—
Pensionand Other Post Retirement Benefit Plans Current
—
Current Debt And Capital Lease Obligation
—
Current Capital Lease Obligation
—
Other Current Liabilities
2.00
Total Non Current Liabilities Net Minority Interest
—
Long Term Debt And Capital Lease Obligation
—
Long Term Debt
—
Long Term Capital Lease Obligation
—
Non Current Deferred Liabilities
129.92
Non Current Deferred Revenue
129.92
Other Non Current Liabilities
—
Stockholders Equity
—
Common Stock Equity
—
Capital Stock
—
Common Stock
—
Preferred Stock
—
Share Issued
—
Ordinary Shares Number
—
Treasury Shares Number
0.12
Additional Paid In Capital
—
Retained Earnings
—
Gains Losses Not Affecting Retained Earnings
—
Other Equity Adjustments
—
Total Equity Gross Minority Interest
—
Total Capitalization
—
Working Capital
—
Invested Capital
—
Total Debt
—
Net Debt
—
Capital Lease Obligations
—
Net Tangible Assets
—
Tangible Book Value
—
Interest Payable
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
55.83
+440.70%
10.32
+114.55%
-70.94
+40.95%
-120.14
Cash Flow From Continuing Operating Activities
55.83
+440.70%
10.32
+114.55%
-70.94
+40.95%
-120.14
Net Income From Continuing Operations
-23.36
+73.43%
-87.94
+46.18%
-163.41
-20.45%
-135.66
Depreciation Amortization Depletion
24.24
+2.60%
23.63
+118.20%
10.83
+234.43%
3.24
Depreciation
—
—
—
3.68
Depreciation And Amortization
24.24
+2.60%
23.63
+118.20%
10.83
+234.43%
3.24
Other Non Cash Items
2.07
-6.85%
2.22
-95.95%
54.82
+324.49%
12.91
Stock Based Compensation
71.42
+47.44%
48.44
+38.32%
35.02
+29.68%
27.01
Provisionand Write Offof Assets
2.89
+10.52%
2.61
-71.76%
9.26
0.00
Deferred Tax
—
0.00
0.00
+100.00%
-6.58
Deferred Income Tax
—
0.00
0.00
+100.00%
-6.58
Operating Gains Losses
-1.72
-39.72%
-1.23
-169.78%
1.76
+294.70%
-0.91
Gain Loss On Investment Securities
—
—
—
-0.91
Net Foreign Currency Exchange Gain Loss
-1.72
-39.72%
-1.23
-169.78%
1.76
0.00
Change In Working Capital
-19.71
-187.27%
22.59
+217.53%
-19.22
+8.69%
-21.05
Change In Receivables
-48.05
-320.58%
-11.43
+74.02%
-43.97
-112.16%
-20.73
Changes In Account Receivables
-48.05
-320.58%
-11.43
+74.02%
-43.97
-112.16%
-20.73
Change In Inventory
-8.45
-166.84%
-3.17
-225.05%
-0.97
+71.75%
-3.45
Change In Prepaid Assets
-5.76
-577.97%
-0.85
+76.42%
-3.60
+2.07%
-3.68
Change In Payables And Accrued Expense
50.10
+24.29%
40.31
+30.98%
30.78
+302.91%
7.64
Change In Payable
50.10
+24.29%
40.31
+30.98%
30.78
+302.91%
7.64
Change In Account Payable
50.10
+24.29%
40.31
+30.98%
30.78
+302.91%
7.64
Change In Other Current Assets
-5.66
-278.04%
-1.50
-193.15%
-0.51
-302.36%
-0.13
Change In Other Current Liabilities
-1.90
-142.46%
-0.78
+16.81%
-0.94
-32.21%
-0.71
Investing Cash Flow
-23.95
+73.42%
-90.12
+15.93%
-107.20
-1492.21%
7.70
Cash Flow From Continuing Investing Activities
-23.95
+73.42%
-90.12
+15.93%
-107.20
-1492.21%
7.70
Net PPE Purchase And Sale
-0.95
+3.93%
-0.99
-811.01%
-0.11
+60.79%
-0.28
Purchase Of PPE
-0.95
+3.93%
-0.99
-811.01%
-0.11
+60.79%
-0.28
Capital Expenditure
-0.95
+95.46%
-20.99
-4.40%
-20.11
-7133.45%
-0.28
Net Investment Purchase And Sale
-23.00
+66.73%
-69.13
-155.01%
125.67
+1475.22%
7.98
Purchase Of Investment
-97.42
-9.43%
-89.03
-225.76%
-27.33
+79.35%
-132.32
Sale Of Investment
74.42
+274.11%
19.89
-87.00%
153.00
+9.05%
140.30
Net Business Purchase And Sale
0.00
0.00
+100.00%
-212.76
0.00
Purchase Of Business
0.00
0.00
+100.00%
-212.76
0.00
Net Intangibles Purchase And Sale
0.00
+100.00%
-20.00
+0.00%
-20.00
0.00
Purchase Of Intangibles
0.00
+100.00%
-20.00
+0.00%
-20.00
0.00
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
40.14
+126.80%
17.70
-94.74%
336.60
+208.56%
109.09
Cash Flow From Continuing Financing Activities
40.14
+126.80%
17.70
-94.74%
336.60
+208.56%
109.09
Net Issuance Payments Of Debt
0.00
0.00
-100.00%
305.30
0.00
Issuance Of Debt
0.00
0.00
-100.00%
305.30
0.00
Long Term Debt Issuance
0.00
0.00
-100.00%
305.30
0.00
Net Long Term Debt Issuance
0.00
0.00
-100.00%
305.30
0.00
Net Common Stock Issuance
0.00
0.00
-100.00%
216.68
+101.82%
107.37
Cash Dividends Paid
—
—
—
—
Proceeds From Stock Option Exercised
40.14
+126.80%
17.70
+69.04%
10.47
+43.98%
7.27
Net Other Financing Charges
—
—
-195.86
-3427.70%
-5.55
Changes In Cash
72.02
+215.96%
-62.10
-139.19%
158.46
+4831.44%
-3.35
Effect Of Exchange Rate Changes
3.22
+348.42%
-1.30
-875.19%
-0.13
-1208.33%
0.01
Beginning Cash Position
222.93
-22.14%
286.33
+123.69%
128.00
-2.54%
131.34
End Cash Position
298.17
+33.75%
222.93
-22.14%
286.33
+123.69%
128.00
Free Cash Flow
54.87
+614.37%
-10.67
+88.28%
-91.05
+24.38%
-120.41
Interest Paid Supplemental Data
12.65
+0.00%
12.65
+85.57%
6.82
0.00
Income Tax Paid Supplemental Data
2.16
+114.84%
1.00
+703.20%
0.12
0.00
Amortization Of Securities
—
—
-1.73
-1.29%
-1.70
Common Stock Issuance
0.00
0.00
-100.00%
216.68
+101.82%
107.37
Interest Paid CFF
—
—
—
—
Issuance Of Capital Stock
0.00
0.00
-100.00%
216.68
+101.82%
107.37
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category